Asia · Markets & Finance · The Edge Singapore

KGI initiates coverage on iX Biopharma with ‘Outperform’ and target price of $1.17

Published by The Edge Singapore · Singapore 17 h ago

The 12-month target price of $1.17, which is based on sum-of-the-parts valuation, implies a 120.8% upside from the last close of 53 cents.

Read the full article on The Edge Singapore Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.theedgesingapore.com)

Also worth reading

SoftBank Robotics, SJ Group partner on AI facilities management

Business Standard

Meesho share price rallies 5%, nears record high in weak market; here's why

The Economic Times

PC Jeweller shares jump 5% to fresh 52-week high, market value swells by Rs 2,500 crore in 4 sessions

The Straits Times Business

NutryFarm shareholders seek CEO’s removal as company pivots from durians to data centres

Hong Kong workers fear AI-driven disruption to retirement but only 20% feel prepared: survey

7 things parents do (unconsciously) that break a child's heart